CN1843460A - Medicine for reducing blood sugar, blood pressure and improving microcirculation and immunity, and its preparation method - Google Patents
Medicine for reducing blood sugar, blood pressure and improving microcirculation and immunity, and its preparation method Download PDFInfo
- Publication number
- CN1843460A CN1843460A CN 200510085788 CN200510085788A CN1843460A CN 1843460 A CN1843460 A CN 1843460A CN 200510085788 CN200510085788 CN 200510085788 CN 200510085788 A CN200510085788 A CN 200510085788A CN 1843460 A CN1843460 A CN 1843460A
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- medicine
- fructus
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention discloses an antihypelipidemic, antihyperglycemic preparation for lowering blood pressure and improving microcirculation blood flow volume, wherein the formulation includes panax ginseng, ophiopogon root, schisandra fruit, wolferry fruit, ligustrum japonicum, kudzu vine root, cassia seed, Siberian solomonseal rhizome, root of red rooted saliva and white atractylodes rhizome.
Description
1. technical field
The present invention relates to the medicine of a kind of blood sugar lowering, blood fat reducing, blood pressure lowering, improvement raising microcirculatory blood flow and immunity, specifically is the Chinese patent medicine of feedstock production with the Chinese herbal medicine.The invention still further relates to the preparation method of this medicine.
2. background technology
Diabetes complicated hyperlipemia, hypertension and retinopathy.Studies show that the patient causes sugar, fat, protein metabolism disorder owing to insulin in the blood lacks relatively or definitely, dysarteriotony causes atherosclerosis and microcirculation disturbance, and hemodynamics changes, fibrinolytic system and platelet function abnormality are assembled, and blood stasis is detained.The traditional Chinese medical science thinks mainly by due to the deficiency of vital energy, the deficiency of YIN, belong to " turbid yin ", " phlegm-damp ", " damp and hot ", etc. category, the blood stasis due to two void can block mechanism of qi, body fluid loses in defeated cloth, channels stasis of blood resistance (little blood vessel, neuropathy) is so multiple complications occurs.
Both at home and abroad to the primary disease Drug therapy, run into following technical barrier at present:
1. hypoglycemic effect is good for Western medicine class (as two flesh classes, iodine ureas, insulin etc.), but side effect is big, and is with infringement liver, kidney and hemocyte, invalid to complication for a long time.
2. Chinese patent medicine class blood sugar reducing function is slow, and effect is not fairly obvious.
3. retinopathy lacks effective medicine at present.
3. summary of the invention:
The purpose of this invention is to provide a kind of blood sugar lowering, blood fat reducing, blood pressure lowering, raising microcirculatory blood flow and immunologic function, alleviate and prevent and treat the medicament of diabetic complication effect.
Another object of the present invention provides this medicaments preparation method.
The present invention is to diabetes (diabetes) and pathogenetic understanding of complication and Therapeutic Principle according to Chinese medicine, with reference to modern pharmacological research achievement and advanced technologies, from natural plant, filter out supplementing QI and nourishing YIN, blood sugar lowering, blood fat reducing, blood pressure lowering, blood circulation and channel invigorating, can improve the medical material of blood microcirculation flow and immunity, by the theory of Chinese medical science prescription, skim the cream off milk with modern advanced technologies, make the integrally-regulated and blood circulation and channel invigorating of its performance, the all methods such as blood flow and immunity that improve cooperate, promote endogenous secretion of insulin, reduce exogenous insulin periphery drag, effective blood sugar regulation, in the time of metabolism disorder of blood lipid, microcirculation improvement is prevented and treated diabetes, hyperlipidemia patient merges cardiovascular pathological changes, retinopathy.
Medicine of the present invention is made (consumption is a weight) by following component:
Radix Ginseng 10-30 part Radix Ophiopogonis 10-20 part Fructus Schisandrae Chinensis 10-20 part
Fructus Lycii 10-25 part Fructus Ligustri Lucidi 15-25 part Radix Puerariae 20-30 part
Semen Cassiae 20-35 part Radix Salviae Miltiorrhizae 10-20 part Rhizoma Polygonati 10-30 part
Rhizoma Atractylodis Macrocephalae 10-25 part
The formula optimization weight proportion scope of preparation medicine of the present invention is:
Radix Ginseng 3-10 part Radix Ophiopogonis 5-15 part Fructus Schisandrae Chinensis 6-10 part
Fructus Lycii 6-15 part Fructus Ligustri Lucidi 10-20 part Radix Puerariae 15-25 part
Semen Cassiae 8-15 part Radix Salviae Miltiorrhizae 5-15 part Rhizoma Polygonati 10-25 part
Rhizoma Atractylodis Macrocephalae 8-15 part
The optimum weight proportioning of medicine of the present invention is:
6 parts of 14 parts of Fructus Schisandrae Chinensis of 8 parts of Radix Ophiopogonis of Radix Ginseng
10 parts of 14 parts of Radix Puerariaes of 14 parts of Fructus Ligustri Lucidi of Fructus Lycii
20 parts of 10 parts of Rhizoma Polygonatis of 9 parts of Radix Salviae Miltiorrhizaes of Semen Cassiae
15 parts of the Rhizoma Atractylodis Macrocephalaes
Above-mentioned each component is made medicine production method of the present invention is:
1. Radix Ginseng, Radix Puerariae, Fructus Ligustri Lucidi is broken by above-mentioned prescription medical material mixed powder, make coarse powder, enable pass is crossed No. 1 sieve or No. 2 sieves, use alcohol reflux, filtration, alcohol extract and medicinal residues are preserved respectively;
2. Radix Ophiopogonis, Fructus Lycii, Fructus Schisandrae Chinensis, Semen Cassiae, Radix Salviae Miltiorrhizae, Rhizoma Polygonati, the Rhizoma Atractylodis Macrocephalae are broken into coarse powder by above-mentioned prescription medical material mixed powder, add above-mentioned medicinal residues (after the alcohol extraction), fry in shallow oil, extract volatile oil and medicinal liquid according to a conventional method with multi-functional pouring water;
3. the decocting medicinal liquid is filtered, clarifies, concentrates;
4. volatile oil is handled with β-CDBao He;
5. add adjuvant (solubilizing agent, antiseptic, antioxidant) after alcohol extract, volatile oil, decocting medicinal liquid being cooperated and obtain dosing;
6. according to a conventional method the Chinese patent medicine dosage form is made in dosing again, as hard capsule, soft capsule, tablet, granule, powder, pill, teabag, medicated wine, oral liquid, distillate medicinal water, injection etc.
An important feature of the present invention is to contain terpenes and flavonoid composition in the medicament, terpenes total content 0.5%-1.0%, flavonoid total content 0.9%-1.8%.Wherein the terpenes composition has good blood sugar lowering, cholesterol reducing effect.Contained flavone compound has very strong oxidation resistance, energy vessel softening, reduction vascular fragility, and microcirculation improvement can reduce too high blood fat, blood pressure, treatment of vascular sclerosis.The terpenes flavone compound has remarkable blood sugar decreasing effect, can increase the islets of langerhans blood perfusion, helps the synthetic and secretion of insulin; Platelet aggregation and thrombosis there are the good restraining effect, can blood circulation promoting and blood stasis dispelling, cleaning blood vessel, blood circulation promoting, raising blood flow; Also has the effect of very strong defying age, enhancing body immunity.
Clinical drug of the present invention uses the result to show that following advantage is arranged:
(1) to select natural edible-plant for use be raw material in the present invention, and each component meets the pharmaceutical control law regulation.Utilize comprehensive function treatment diabetes, hyperlipidemia, hypertension and the complication of prescription medicine, nontoxic, harmless to human body.
(2) select alcohol extracting method and use multi-functional extraction to irritate and extract active ingredient for use, the drug bioavailability height reaches quick-acting, purpose efficiently.
(3) diabetes and hyperlipidemia complications, hypertension and retinopathy there is good therapeutic effect.
For showing the present invention to the treatment of diabetes effect, through the clinical observation of 100 routine systems, and selection medical history, the state of an illness, age, sex and suitable diabetics 50 examples of former Therapeutic Method are matched group.From being in hospital and endocrine special outpatient clinic selection case, press the diabetes diagnosis standard that WHO1980 formulates, the maturity-onset diabetes patient who makes a definite diagnosis, on the basis of Diet Therapy method and medicine (oral antidiabetic drug and insulin) treatment, fasting glucose 7.2mmoI/L person is the object of observation, wherein male 48 examples, women 52 examples, age 27-50 year, course of disease half a year to 20 year.Test group: on former treatment basis, the lipid lowerers of stopping using is obeyed medicine of the present invention.Matched group: blood sugar lowering, blood fat reducing treatment routinely, wherein hypoglycemic medicine, kind instructions about how to take medicine consumption and test group are complementary, and lipid lowerers adopts the import fenofibrate.Adopt same procedure to make regular check on fasting glucose and blood fat, two months observation periods, 20 days is a course of treatment, totally three courses of treatment.
Instructions of taking: oral liquid of the present invention 20ml/ time, day clothes 3 times, ante cibum, boiled water was taken after mixing it with water.Clinical test results such as subordinate list 1-2.
Subordinate list 1 is taken medicine of the present invention front and back insulin, and diamicron is with being and change of blood sugar
| Case load | Insulin dosage (U/d) | Diamicron consumption (mg/d) | Fasting glucose decline (mmol/L) | |||
| Before | After | Before | After | Before | After | |
| Test group 100 matched groups 50 T P | 46.2 45.89 0.28 ＞0.05 | 20.59 49.18 10.87 ＜0.01 | 260 240 0.26 ＞0.05 | 60 280 8.75 ＜0.01 | 11.7±3.69 11.37±3.18 0.54 ＞0.05 | 7.55±2.32 9.78±3.01 2.46 ＜0.01 |
Subordinate list 2 is taken medicine front and back lipid lowerers consumption of the present invention and the average concentration change of blood fat
| Case load | Fenofibrate consumption (U/d) | Serum cholesterol meansigma methods (mg/d) | Serum glycerol meansigma methods (mmol/L) | |||
| Before | After | Before | After | Before | After | |
| Test group 100 | 0 | 0 | 5.77±1.10 | 4.52±0.82 | 2.12±1.07 | 1.34±0.53 |
| Matched group 50 T P | 300 | 300 | 5.87±1.06 0.84 ＞0.05 | 5.13±0.97 4.32 ＞0.01 | 2.08±0.93 0.76 ＞0.05 | 2.51±0.32 3.55 ＞0.05 |
From subordinate list 1 as can be seen, fasting glucose concentration is similar substantially with the hypoglycemic medicine consumption before two groups of tests, P＜0.05, and blood glucose descended after test group was taken the present invention, and the antidiabetic drug consumption is but than original minimizing 1/3-1/2.
Subordinate list 2 data show that serum cholesterol and triglyceride mean concentration do not have significant difference before two groups of tests; But test group is not used any other lipid lowerers with behind the medicine of the present invention, can reach the blood fat reducing purpose.
Take the relevant data of immunity of organisms before and after the medicine of the present invention, measurement result 3 (matched group is the normal person, and test group is the diabetes patient) of seeing attached list.
Subordinate list 3T Lymphocyte Subsets Determination result
| The example number | OKT(％) | OKT 4(％) | OKT 3(％) | OKT 4 OKT 3 | ||
| Test group | Before the treatment | 50 | 64.47±6.23 | 36.47±4.27 | 31.48±3.68 | 1.27±0.14 |
| Before the treatment | 50 | 64.37±7.28 | 38.91±4.12 | 27.57±4.32 | 1.43±0.32 | |
| Matched group | 40 | 64.36±8.70 | 38.91±4.11 | 25.43±4.18 | 1.46±0.24 | |
The detection method of T cell mass is to adopt conventional alkaline phosphorus enzyme alkali resistance phosphoric acid enzyme process.Determination data shows that diabetics is OKT before taking medicine of the present invention
3Be significantly higher than the normal person, OKT
4/ OKT
3Ratio obviously reduces, and takes after the medicine of the present invention, and the two all roughly recovers normal, shows that medicine of the present invention has the enhancing human body immunity function.
Test statistics shows: with medicament of the present invention 100 diabeticss are done therapeutic test, that obtains significant curative effect accounts for 53%, substantially effectively accounts for 42%, and invalid accounts for 5%, and total effective rate reaches 95%.
4. the specific embodiment
Embodiment: take by weighing raw material by following proportioning
Radix Ginseng 8kg Radix Ophiopogonis 14kg Fructus Schisandrae Chinensis 6kg
Fructus Lycii 14kg Fructus Ligustri Lucidi 14kg Radix Puerariae 10kg
Semen Cassiae 9kg Radix Salviae Miltiorrhizae 10kg Rhizoma Polygonati 20kg
Rhizoma Atractylodis Macrocephalae 15kg
Production method is as follows:
Earlier Radix Ginseng, Radix Puerariae, Fructus Ligustri Lucidi are mixed by above-mentioned prescription and pulverize, making can be by the coarse powder of No. 1 or No. 2 sieve, and with 75% ethanol (8 times of amounts) reflux, extract, 2 hours, filtration, alcohol extract and medicinal residues are preserved respectively; Again Radix Ophiopogonis, Fructus Lycii, Fructus Schisandrae Chinensis, Semen Cassiae, Radix Salviae Miltiorrhizae, Rhizoma Polygonati, the Rhizoma Atractylodis Macrocephalae are broken into coarse powder by above-mentioned prescription mixed powder; Rough segmentation is added 2 water loggings bubble 1 hour, adds the medicinal residues behind the alcohol extract again,, each 8 times of water, fried in shallow oil 1 hour, extract volatile oil and medicinal liquid according to a conventional method with " multi-function extractor " decocting 3 times, medicinal liquid is left standstill filter just after, make with supercentrifugal process and to fry in shallow oil the soup purification; Medicinal liquid is concentrated the concentration that reaches each everyone dose 20ml; Dosing: the alcohol extract behind concentrated solution, volatile oil (β-CDBao He), the recovery ethanol is mixed interpolation suitable antiseptic, antioxidant, correctives and solubilizing agent; The timely fill of the medicinal liquid for preparing in aseptic clean dried easy-open lid bottle (20ml/ props up), is added a cover obturation, 100 ℃ of flowing steam sterilization 30min.Make oral liquid.
Claims (6)
1. the medicine of a blood sugar lowering, blood fat reducing, blood pressure lowering, microcirculation improvement blood flow and immunologic function is characterized in that it is the medicament of being made by the following weight proportion raw material.
Radix Ginseng 10-30 part Radix Ophiopogonis 10-20 part Fructus Schisandrae Chinensis 10-20 part
Fructus Lycii 10-25 part Fructus Ligustri Lucidi 15-25 part Radix Puerariae 20-30 part
Semen Cassiae 20-35 part Radix Salviae Miltiorrhizae 10-20 part Rhizoma Polygonati 10-30 part
Rhizoma Atractylodis Macrocephalae 10-25 part.
2. according to the described medicine of claim 1., wherein the weight proportion of each raw material is
Radix Ginseng 3-10 part Radix Ophiopogonis 5-15 part Fructus Schisandrae Chinensis 6-10 part
Fructus Lycii 5-15 part Fructus Ligustri Lucidi 10-20 part Radix Puerariae 15-25 part
Semen Cassiae 8-15 part Radix Salviae Miltiorrhizae 5-15 part Rhizoma Polygonati 10-25 part
Rhizoma Atractylodis Macrocephalae 8-15 part.
3. according to the described medicine of claim 1., wherein the weight proportion of each raw material is
6 parts of 14 parts of Fructus Schisandrae Chinensis of 8 parts of Radix Ophiopogonis of Radix Ginseng
10 parts of 14 parts of Radix Puerariaes of 14 parts of Fructus Ligustri Lucidi of Fructus Lycii
20 parts of 10 parts of Rhizoma Polygonatis of 9 parts of Radix Salviae Miltiorrhizaes of Semen Cassiae
15 parts of the Rhizoma Atractylodis Macrocephalaes.
According to claim 1., 2. or 3. described medicines, it is characterized in that said medicament is the above dosage form of saying of any pharmaceutics.
5. according to the described medicine of claim 4., it is characterized in that said medicament is mixture or oral liquid.
6. the preparation method of claim 4. or 5. described medicines is characterized in that getting Radix Ginseng, Radix Puerariae, Fructus Ligustri Lucidi and mixes to pulverize by formula proportion and make coarse powder, and with alcohol reflux, filtration, alcohol extract and medicinal residues are preserved respectively; Get Fructus Lycii, Radix Ophiopogonis, Fructus Schisandrae Chinensis, Semen Cassiae, Radix Salviae Miltiorrhizae, Rhizoma Polygonati, Rhizoma Atractylodis Macrocephalae mixed powder and be broken to coarse powder, add the medicinal residues after the alcohol extraction, reuse " multi-functional extraction filling " decocting extracts volatile oil and medicinal liquid (concentrating) according to a conventional method; Adding adjuvant after the medicinal liquid mixing before alcohol extract, volatile oil, the water, formulation method is prepared into required dosage form routinely.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100857881A CN100488546C (en) | 2005-08-16 | 2005-08-16 | Medicine for reducing blood sugar, blood pressure and improving microcirculation and immunity, and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100857881A CN100488546C (en) | 2005-08-16 | 2005-08-16 | Medicine for reducing blood sugar, blood pressure and improving microcirculation and immunity, and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1843460A true CN1843460A (en) | 2006-10-11 |
| CN100488546C CN100488546C (en) | 2009-05-20 |
Family
ID=37062446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100857881A Expired - Fee Related CN100488546C (en) | 2005-08-16 | 2005-08-16 | Medicine for reducing blood sugar, blood pressure and improving microcirculation and immunity, and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100488546C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103721187A (en) * | 2013-12-20 | 2014-04-16 | 安徽金太阳生化药业有限公司 | Blood-circulation-promoting and blood-fat-reducing pill for treating hyperlipemia and preparation method of pill |
| CN105250494A (en) * | 2015-10-30 | 2016-01-20 | 华北理工大学 | Traditional Chinese medicine recipe for improving glycometabolism and preparation process |
| CN106214922A (en) * | 2016-08-26 | 2016-12-14 | 吕晶晶 | A kind of Chinese medicine composition treating hypertension and preparation method thereof |
-
2005
- 2005-08-16 CN CNB2005100857881A patent/CN100488546C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103721187A (en) * | 2013-12-20 | 2014-04-16 | 安徽金太阳生化药业有限公司 | Blood-circulation-promoting and blood-fat-reducing pill for treating hyperlipemia and preparation method of pill |
| CN105250494A (en) * | 2015-10-30 | 2016-01-20 | 华北理工大学 | Traditional Chinese medicine recipe for improving glycometabolism and preparation process |
| CN106214922A (en) * | 2016-08-26 | 2016-12-14 | 吕晶晶 | A kind of Chinese medicine composition treating hypertension and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100488546C (en) | 2009-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1224614A (en) | Medicine for preventing and curing cardiac and cerebral vascular diseases and its preparation | |
| CN108404062B (en) | Traditional Chinese medicine composition for treating hyperlipidemia and preparation method and application thereof | |
| CN1839944A (en) | Granular composition for reducing blood fat and process for producing the same | |
| CN1939506B (en) | Preparation with blood-pressure, blood-sugar and blood-fat lowering functions and its making method | |
| CN1853702A (en) | Chinese medicinal preparation for lowering blood sugar, blood fat and blood pressure, improving blood flow and immune and its making method | |
| CN101496894B (en) | Medicament for treating fatty liver and preparation method thereof | |
| CN100488546C (en) | Medicine for reducing blood sugar, blood pressure and improving microcirculation and immunity, and its preparation method | |
| CN1857599A (en) | Medicine for lowering blood sugar, blood fat and blood pressure, raising blood flow rate and raising immunity and its preparing method | |
| CN102178733A (en) | Chinese medicinal preparation for treating diabetes and preparation method thereof | |
| CN1149097C (en) | Chinese patent medicine for curing diabetes | |
| CN1957972A (en) | Composition in use for invigorating primordial energy, benefiting pubic region, preparation method and usage | |
| CN1256967C (en) | Health-preserving liver-protecting drug and method for making same | |
| CN101041037A (en) | Drug for curing diabetes and nephropathy and its preparing method | |
| CN1430982A (en) | Capsule of astragalus and honey as well as its preparing technique | |
| CN1857605A (en) | Medicine for treating chronic alcoholic hepatopathy and its preparing method | |
| CN1272054C (en) | Medicine for treating diabetes and its preparing process | |
| CN1063649C (en) | Red ginseng and hawthorn fruit health-care wine | |
| CN1183936C (en) | Medicine for treating hypertension and method for preparing medicinal tea thereof | |
| CN1176794A (en) | Medicine for treating masculine sterility | |
| CN111000969A (en) | Pharmaceutical composition for treating simple obesity and preparation method thereof | |
| CN100337639C (en) | Concentrated life-cultivating blood-sugar reducing beverge | |
| CN100339119C (en) | Traditional Chinese medicine prepns. for treating diabete | |
| CN102614271A (en) | Chinese medicine for treating diabetic dyslipidemia | |
| CN1097333A (en) | A kind of pure plant health preparation glycolipid disappears and method for making | |
| CN1279961C (en) | Chinese prepared drug formulation for stopping cough and eliminating sputum and its preparation process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING HONG SENG MEDICINE SCIENCE AND TECHNOLOGY Free format text: FORMER OWNER: YANG JIXING Effective date: 20091225 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20091225 Address after: Beijing Daxing District biomedical industry base, 9 Fu Tian street, No. 12, building Patentee after: Beijing Gangsheng Pharmaceutical Technology Co., Ltd. Address before: Shanxi City Development Zone in Linfen province river Fen road Qimao City Huagang Patentee before: Yang Jixing |
|
| DD01 | Delivery of document by public notice |
Addressee: Yang Jixing Document name: Notification to Pay the Fees |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090520 Termination date: 20130816 |